-
02:20:59 PM

BIIB Stock News

09/06/23 9:00 AM
Nasdaq : BIIB
Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management
Octave ® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis and other neurodegenerative diseases, announced today that it plans to conduct an observational, real-world study with Biogen as the sponsor. The study will utilize the Octave ® Precision Care Solution to evaluate 150 patients with MS...
RHEA-AI
positive
08/04/23 10:41 PM
Nasdaq : BIIB
clinical trialfda approval
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45 Mental health conditions are the leading cause of maternal mortality
RHEA-AI
neutral
07/19/23 7:30 PM
Nasdaq : BIIB
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer’s disease New data on subcutaneous formulation shows promising PK /PD data modeling on efficacy and safety, representing a potential new option for administering
RHEA-AI
neutral